

(2) seeding and culturing the *E. coli* strain W host cell in a suitable culture medium; such that the industrial process produces the heterologous protein.

C<sup>1</sup> 22. The process of claim 21, wherein the *E. coli* strain W host cell is from the strain designated ATCC 9637.

23. The process of claim 21, wherein the *E. coli* strain W host cell is a derivative of the strain designated ATCC Number 9637 and is obtained by clonal selection or genetic manipulation.

C<sup>2</sup> 39. The process of claim 21, wherein the suitable system for expressing heterologous proteins comprises the nucleic acid sequence of SEQ ID NO: 1.

43. An *E. coli* strain W host cell, comprising a suitable system for expressing heterologous proteins, wherein the suitable system comprises the *P<sub>trp</sub>* promoter.

C<sup>3</sup> 44. The *E. coli* strain W host cell of claim 43, wherein the suitable system for expressing heterologous proteins comprises the nucleic acid sequence of SEQ ID NO: 1.

#### REMARKS

The Office Action of September 30, 2002 has been carefully considered and the following response prepared. Claims 21-44 are pending. Claim 38 has been canceled without prejudice. Claims 21, 22, 23, 39, 43 and 44 have been amended.

At page 2 of the Office Action, the Examiner, the Examiner advised Applicants that the Information Disclosure Statement filed March 5, 2002 fails to comply with 37 CFR 1.98(a)(3) because it does not contain a concise explanation of the relevance of each patent that is not in the English language. The Examiner further stated that the Information Disclosure Statement has been placed in the application file, but the information referred to therein has not been considered and the relevant references are